Why the study?
Does intravenous administration of bioactive silicon ions improve cardiac function and stimulate angiogenesis post-myocardial infarction in preclinical models?
Does intravenous administration of bioactive silicon ions improve cardiac function and stimulate angiogenesis post-myocardial infarction in preclinical models?
Intravenous administration of bioactive silicon ions represents a novel 'ion therapy' strategy that promotes angiogenesis and improves cardiac function post-myocardial infarction in preclinical models.
Although numerous therapies are widely applied clinically and stem cells and/or biomaterial based in situ implantations have achieved some effects, few of these have observed robust myocardial regeneration. The beneficial effects on cardiac function and structure are largely acting through paracrine signaling, which preserve the border-zone around the infarction, reduce apoptosis, blunt adverse remodeling, and promote angiogenesis. Ionic extracts from biomaterials have been proven to stimulate paracrine effects and promote cell-cell communications. Here, the paracrine stimulatory function of bioactive ions derived from biomaterials is integrated into the clinical concept of administration and proposed "ion therapy" as a novel strategy for myocardial infarction. In vitro, silicon- enriched ion extracts significantly increase cardiomyocyte viability and promote cell-cell communications, thus stimulating vascular formation via a paracrine effect under glucose/oxygen deprived conditions. In vivo, by intravenous injection, the bioactive silicon ions act as "diplomats" and promote crosstalk in myocardial cells, stimulate angiogenesis, and improve cardiac function post-myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Advanced Science